As of Dec. 16, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
Here's the latest list of major overbought players in this sector.
Avidity Biosciences Inc (NASDAQ:RNA)
- On Nov. 10, Avidity Biosciences reported quarterly losses of $1.27 per share which missed the analyst consensus estimate of losses of $1.11 per share. The company reported quarterly sales of $12.475 million which beat the analyst consensus estimate of $1.932 million. “In October, we announced that Avidity entered into a definitive merger agreement with Novartis, which we believe maximizes value for our investors, accelerates the global reach of our innovative neuroscience pipeline, and advances even more possibilities for our innovative science,” said Sarah Boyce, president and chief executive officer of Avidity. The company's stock gained around 141% over the past six months and has a 52-week high of $71.90.
- RSI Value: 76
- RNA Price Action: Shares of Avidity Biosciences rose 0.04% to close at $71.86 on Monday.
- Edge Stock Ratings: 95.79 Momentum score.
Henry Schein Inc (NASDAQ:HSIC)
- On Dec. 9, Barclays analyst Glen Santangelo initiated coverage on Henry Schein with an Overweight rating and announced a price target of $86. The company's stock gained around 6% over the past five days and has a 52-week high of $82.49.
- RSI Value: 71.1
- HSIC Price Action: Shares of Henry Schein rose 1.1% to close at $77.39 on Monday.
Curious about other BZ Edge Rankings? Click here to discover how similar stocks measure up.
Read This Next:
Photo via Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
